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Several recently developed technologies for molecular imaging have been applied to magnetic resonance (MR)
imaging for cancer. In particular, various MR sequences with biocompatible polymer-based magnetic nanopar-
ticles (pMNPs) have been applied for the MR imaging of cancer. However, there are several limitations to this
approach, and passive contrast agents are not yet sufficiently targeted. This is a particular challenge for gastric
cancer owing to the interference from stomach contents. Therefore, in this study we developed targeting con-
trast agent and assessed its feasibility for early gastric cancer diagnosis using a mouse model. Specifically, we
synthesized pMNPs, which enable both T2-weighted (T2) and ultra-short TE (UTE) MR imaging using hyal-
uronic acid as the polymer, which binds to the receptor CD44, a recently identified biomarker of gastric cancer.
Both MR sequences (T2, UTE) were analyzed with respect to imaging effects and targeting to the pMNPs. In
vitro assessments showed no significant cytotoxicity of the pMNPs to MKN-45 and MKN-28 cells and con-
firmed the cellular uptake of the pMNPs. MR signal enhancement was identified after pMNPs injection to the
mice, and the pMNPs gradually accumulated in the tumors. Based on the results, we suggest that pMNPs serve
as useful probes for imaging stem-like cancer cells, and can further provide new possibilities by simultaneously
confirming T1 and T2 MR imaging effects.
Keywords : molecular imaging, T2 MRI, UTE MRI, magnetic nanoparticles, gastric cancer, CD44, magnetic reso-
nance imaging
1. Introduction
Molecular imaging is an invaluable tool to diagnose
cancer at the cellular and molecular levels [1]. Molecular
imaging not only allows for early and accurate tumor
localization in diagnostic cancer imaging but also has
potential to allow visualization of the biological processes
of tumor growth, metastasis, and response to treatment in
real-time clinical monitoring [2-6]. Molecular magnetic
resonance (MR) imaging has emerged as a key modality
for the diagnosis of cancer, owing to its advantages of
non-invasiveness, good anatomical imaging given the
high resolution and high contrast, and ability to provide
three-dimensional information in real time that is not
possible with other imaging modalities such as positron
emission tomography, single-photon emission computed
tomography, and optical imaging [7]. Furthermore, mole-
cular MR imaging can simultaneously detect the meta-
bolism of cells and tissues along with physiological and
structural information in a non-invasive manner, provid-
ing quantitative information on the biological processes
occurring in the deep tissues [8]. 
Multimodal imaging strategies integrating manifold
images have improved our ability to diagnose, to guide
therapy, and to predict outcomes. Magnetic resonance
imaging (MRI) is among the most widely used imaging
technique in the clinic and can enable multi-parameter
anatomical demonstration of diagnosis. Due to the inherent
black-and-white production of MR images, however,
MRI detection is largely hampered by the occurrence of
false-positive diagnoses. In this Perspective, many research
groups introduce the paradigm of manipulating the multi-
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parameter MRI, T1–T2 dual-modal MRI, along with
enhancement by specific contrast agents. Although mole-
cular MR imaging is widely applied to visualizing lesions
in multi-modalities for the diagnosis of gastric cancer, it
also has important limitations [9]. In particular, it is
difficult to diagnose gastric cancer based on MR images
due to the interference by food and other digestive-system
secretions in the stomach [10]. Extensive research effort
has focused on development of updated MR technologies
for gastric cancer diagnosis, demonstrating that these
limitations can be overcome through the use of various
MR sequences. A single MR image is obtained through
the acquisition of various images via a sequence of operations
that serves as significantly favorable factors [11]. There-
fore, from a diagnostic point of view, simultaneously
observing the T1-T2 effect using conventional T2 and
ultra-short TE (UTE) is of great significance [12]. In
particular, the ultra-short TE sequence allows for detec-
tion of all components except for water associated with
collagen, which has ultra short transverse relaxation (T2*
less than 20 μs). Compared with conventional sequences,
detection of these additional components may be useful in
determining early stages of disease [13]. Nevertheless,
there are still limitations to this approach. There are many
MR contrast agents available for good-quality imaging
[14]; however, passive contrast agents are not sufficient to
reach their targets due to charge effects [15]. Because
passive targeting facilitates deposition of nanovectors
within the tumor microenvironment, owing to distinctive
characteristics inherent to the tumor milieu, not normally
present in healthy tissues. The delivery of nanoparticles is
determined by factors associated with the tumor micro-
vasculature, in addition to factors inherent to the nano-
particle itself, such as size, shape and surface charge.
Targeting strategies have taken a step further to enhance
the selective uptake of nanoparticles into the tumor cells.
Biorecognition molecules have been attached to the surface
of the nanovectors to target specific markers that are
overexpressed by the neoplastic cells. These strategies
have been awarded the appellation ‘active targeting’,
which exhibits a higher specificity and efficacy in achiev-
ing the desired goal [16]. Thus, we are aiming to develop
the targeting contrast agent. 
In this study, we designed biocompatible polymer (HA)-
conjugated magnetic nanoparticles (pMNPs) for use in
molecular MR imaging in a heterotopic xenograft gastric
cancer model to elucidate the detailed biological processes
occurring in gastric cancer. T2 sequence and UTE sequences
were simultaneously used to confirm the better diagnostic
potential and targeting effect of the pMNPs, and various
in vitro and in vivo experiments were conducted to evaluate
the specific binding affinity and diagnostic effectiveness.
2. Materials and Methods
2.1. Synthesis of magnetic nanoparticles
To synthesize monodispersed MNPs, 2 mmol of iron
(III) acetylacetonate, 1 mmol of manganese(II) acetyl-
acetonate, 10 mmol of 1,2-hexadecanediol, 6 mmol of
dodecanoic acid, and 6 mmol of dodecylamine were
dissolved in 20 mL of benzyl ether under an ambient
nitrogen atmosphere. The mixture was then pre-heated to
200 °C for 2 h and refluxed at 300 °C for 30 min. After
the reactants were cooled at room temperature, the pro-
ducts were purified with an excess of pure ethanol.
Approximately 12 nm of MNPs were synthesized using
the seed-mediated growth method.
2.2. Synthesis of aminated polysorbate 80
Aminated polysorbate 80 was synthesized using 1,1’-
carbonyldiimidazole (CDI). In brief, 5 mmol of poly-
sorbate 80 and 15 mmol of CDI (both from Sigma-
Aldrich Chemical Co., St. Louis, MO, USA) were dis-
solved in a flask containing 100 mL 1,4-dioxane (99.8 %;
Sigma-Aldrich) and the reactant solution was stirred for 1
h. Subsequently, 15 mmol of ethylenediamine (Sigma-
Aldrich) was added to the reactor at room temperature.
After further reaction for 24 h, the solvent was rapidly
eliminated using a rotary evaporator. The obtained trans-
parent gel-type product was dissolved in 10 mL of deionized
water and dialyzed against the excess aqueous phase for
over seven days with a dialysis membrane (molecular
weight cut-off: 1,000 Da; Spectrum Laboratory). The puri-
fied product was freeze-dried and stored under vacuum
for later use. The characteristic bands of synthesized poly-
sorbate 80 were confirmed by Fourier-transform infrared
spectroscopy (FT-IR; Varian, Excalibur® series). Ultrapure
deionized water was used for all synthesis reactions. 
2.3. Phase transfer of nanoparticles with aminated
polysorbate 80 
pMNPs were prepared by the nanoemulsion method.
MNPs (30 mg) were dissolved in 4 mL hexane (as the
organic phase), and the organic phase was mixed with 20
mL of deionized water (as the aqueous phase) containing
100 mg aminated polysorbate 80. After mutual saturation
of the organic and aqueous phases, the emulsion was
ultra-sonicated in an ice-cooled bath for 20 min at 190 W.
The organic solvent was evaporated overnight at room
temperature, and the products were purified by centrifugal
filtration (Centriprep YM-3, 3,000 Da, Amicon) with two
cycles at 3,000 rpm for 1 h. The size distribution and
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zeta-potential were analyzed by laser scattering (ELS-Z,
Otsuka Electronics). The morphologies of the phase-
transferred MNPs were confirmed using transmission
electron microscopy (JEM-2100, JEOL Ltd.).
2.4. Bioconjugation of nanoparticles with the polymer
(HA)
For the fabrication of taretable nanoprobes, HA, as a
biocompatible polymer, was used as a targeting moiety by
conjugation to the surface functional group of the pMNPs
via N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydro-
chloride (EDC) and N-hydroxysulfosuccinimide (sulfo-
NHS), both obtained from Pierce. Thirty milligrams of
HA (1,000,000 Da; Yuhan Pharmaceutical Corporation,
Seoul, Korea) was dissolved in 10 mL phosphate-buffered
saline (PBS, 10 mM, pH 7.4; Yuhan Pharmaceutical) and
mixed with the MNPs. Sulfo-NHS (1.7 mg) and EDC
(1.5 mg) were then added to the mixed polymer (HA) and
MNP solution (pMNPs). The products were purified by a
syringe filter, followed by centrifugal filtration (Centriprep
YM-3, 3,000 Da, Amicon) with two cycles at 3,000 rpm
for 20 min each. 
2.5. Cytotoxicity assay
The cytotoxic effect of the pMNPs against MKN-45
and MKN-28 gastric cancer cells (American Type Culture
Collection) was evaluated by measuring the inhibition of
cell growth using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. MKN-45 and
MKN-28 cells were maintained in Roswell Park Memorial
Institute-1640 (RPMI-1640) medium, containing fetal
bovine serum and antibiotic-antimycotic solution (all from
Gibco) at 37 °C in a humidified atmosphere with 5 %
CO2. MKN-45 and MKN-28 cells (1.0 × 10
4 cells/well)
were plated in a 96-well plate and incubated at 37 °C
overnight, and then treated with various concentrations of
the pMNPs for 24 h. The MTT assay was then performed,
in which yellow tetrazolium salt was reduced to purple
formazan crystals in metabolically active cells. The
relative percentage of cell viability was determined as the
ratio of formazan intensity in viable cells treated with
pMNPs to the intensity in non-treated (control) cells. Cell
viability was normalized to the value of non-treated cells
(considered as demonstrating 100 % cell viability).
2.6. Darkfield microscopy
Darkfield microscopy is commonly applied to exclude
the unscattered beams from the image so that the field
around the specimen is generally dark. However, nano-
particles under the same brightness scatter more than the
cellular matrix, and thus shine brightly so that they are
visible as white spots. Thus, darkfield microscopy is a
very simple, effective, and low-cost technique for confirm-
ing interactions between nanoparticles and cells. MKN-45
cells (2.0 × 105 cells/well) were seeded onto cover glasses
in 4-well plates and incubated for 4 h at 37 °C. Prepared
MNPs and pMNPs (10 μg/mL) were added to Dulbecco’s
modified Eagle’s medium (Roswell Park Memorial Institute,
USA). After incubation for 48 h at 37 °C, the cells were
washed with PBS and fixed with 4 % paraformaldehyde.
To observe the optical absorption of the MNPs and
pMNPs in the cells, light-scattering images were obtained
using an inverted microscope (Olympus BX51, Japan)
with a highly numerical darkfield condenser (U-DCW,
Olympus), which delivers a very narrow beam of white
light from a tungsten lamp to the surface of the sample.
Immersion oil (nd: 1.516, Olympus) was used to narrow
the gap between the condenser and the glass slide and to
balance the refractive index. The darkfield pictures were
captured using an Olympus CCD camera (Lee et al.,
2012, 465101).
2.7. Prussian blue staining
Prussian blue staining is a commonly used histopatho-
logy method to detect the presence of iron in specimens.
Any ferric ion present in the specimens combines with the
ferrocyanide and results in the formation of a bright blue
color. As a result, the presence of a small amount of iron
contained in the nanoparticles in cells or tissues can be
confirmed. MKN-45 and MKN-28 cells (1.0 × 106 cells/
well) were seeded onto 6-well plates with RPMI medium,
and incubated for various times at 37 °C. Various con-
centrations of prepared MNPs and pMNPs were added to
the wells. After incubation for 4 h at 37 °C, the cells were
washed with PBS and fixed with 4 % paraformaldehyde.
The cells were then treated with a 1:1 mixture of 10 %
potassium ferrocyanide and 20 % HCl, followed by
incubation at 30 min at room temperature. The mixed
solution was washed and the cells were stained with
Nuclear Fast Red solution (Sigma-Aldrich) for 30 min at
room temperature. The cells were observed using an
optical microscope system (Olympus BX51, Japan).
2.8. Animal model and experimental procedures
All animal experiments were conducted with the approval
of the Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC) International. Male
BALB/C-Slc nude mice at 7–8 weeks of age were
anesthetized by intraperitoneal injection of a Zoletil/
Rompun mixture and injected with 200 mL of 1.0 × 107
MKN-45 cells suspended in saline into the femoral region.
MR imaging was performed between 2 and 3 weeks after
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cancer cell implantation, followed by organ MR imaging.
In addition, the extracted tumor tissues from tumor-bearing
mice treated with pMNPs were frozen, sectioned, and
stained using Prussian blue as described above. All stained
tissue sections were analyzed using a virtual microscope
(Olympus BX51, Japan) and Olyvia software. The overall
experimental design is schematically illustrated in Scheme 1.
2.9. MR imaging 
Animal, organ, and solution MR imaging experiments
were performed on a 3 Tesla clinical MRI instrument
using a wrist coil supplied by the same manufacturer
(Magnetom Vida, Siemens Healthcare, Erlangen, Germany)”.
Sequence details (commercial clinical product sequences):
Ultra short TE (TR: 6.72 ms; TE: 0.07 ms, slice thick-
ness: 0.6 mm, FOV read: 110 mm, flip angle: 4°, in-plane
resolution: 0.28 mm, scan time: 10.24 min) and T2 Turbo
spin echo (TR: 4000 ms, TE: 114 ms, slice thickness: 1.0
mm, FOV read: 180 mm, flip angle: 60-180°, in-plane
resolution: 0.469 mm, scan time: 11 min)
3. Results
3.1. Preparation of MNPs and pMNPs
As shown in Fig. 1, the characteristic band of pMNP
conjugates was verified by FT-IR spectra, which exhibited
O-H stretching at 3200–3400 cm1, C=O stretching at
1100–1300 cm1, CO-NH (amide) bonds at 1630–1680
cm1, and CH2 bending in the polymer (HA) at 1430–1470
cm1. As MR agents, uniform MNPs (12.38 ± 1.0 nm)
were synthesized at a high temperature via a thermal
decomposition process. The size distribution and morpho-
logy of the MNPs were confirmed by transmission electron
microscopy (Fig. 2), which showed no significant differ-
ences in size or morphology between pMNPs and MNPs.
The size of the water-soluble MNPs and pMNPs was
determined to be 77.4 ± 32.4 nm and 137 ± 53.2 nm,
respectively. In addition, the surface charge of aminated
MNPs also changed from 20.62 ± 1.96 Mv (aminated
water-soluble MNPs) to -17.76 ± 1.64 mV (pMNPs) due
to the presence of HA (Fig. 3). 
3.2. Solubility and intensity of pMNPs 
Sequence details: Ultra short TE (TR: 6.72 ms; TE:
0.07 ms, slice thickness: 0.2 mm, flip angle: 4°, in-plane
Scheme 1. (Color online) Schematic illustration of T2-weighed RF and UTE RF molecular MR imaging using polymer-based mag-
netic nanoparticles in a mouse gastric cancer model. 
Fig. 1. (Color online) FT-IR spectra of the polymer (HA, black
line), MNPs (green line), and pMNPs (red line) (NH2 : 1538
cm1, Amide : 1650 cm1, C-N : 1100 cm1 ). This data proved
that each synthesis step was successfully synthesized.
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resolution: 0.28 mm, scan time: 10.24 min) and T2 Turbo
spin echo (TR: 4000 ms, TE: 114 ms, slice thickness: 0.2
mm, flip angle: 60-180°, in-plane resolution: 0.469 mm,
scan time: 11 min)
3.3. Biocompatibility
We showed that the MKN-45 and MKN-28 cells retain-
ed over 80 % viability based on the concentration of 0.4
μg Fe + Mn/mL after pMNP treatment in vitro (Fig. 5),
indicating that the pMNPs are biocompatible even at high
concentrations. 
3.4. In vitro binding efficacy of pMNPs 
Darkfield microscopy images demonstrated that the
pMNPs displayed excellent binding ability to MKN-45
cells (Fig. 6). MKN-45 cells treated with pMNPs exhibited
Fig. 2. Transmission electron microscopy (TEM) images of (a) MNPs and (b) pMNPs (scale bars = 100 nm). (a) MNPs were before
coating with polymer and PMNPs were after coating with polymer. Magnetic nanoparticles have a uniform size of 12.38 ± 1.0 nm
(100 particles were measured).
Fig. 3. Average size (gray bars) and zeta potential (black cir-
cles) of MNPs and pMNPs The size of MNPs and pMNPs was
determined to be 77.4 ± 32.4 nm and 137 ± 53.2 nm, respec-
tively. 
Fig. 4. (Color online) (a) Sample photograph and solution MR
images (T2 and UTE MR sequence) under each condition
(0.87 to 0.09 mM) and (b) T2 and UTE intensities based on
(a).
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a bright spot, and the membranes of pMNP-treated MKN-
45 cells shone more brightly compared to those of the
non-treated MKN-45 cells. The cells were incubated for 4
h with 10 μg/mL pMNPs. The scale bar represents 20 μg/
mL. As shown in Fig. 7, The cells were incubated for 4 h
with 40 μg/mL pMNPs. The scale bar is 10 μm. Numer-
ous blue spots, produced by the rapid exchange of electrons
between Prussian blue and the ferric ions of the pMNPs,
appeared in the intracellular region. And MKN-28 is
CD44 negative cell line, MKN-45 is CD44 positive cell
line, pink color represents cells and blue color represents
magnetic nanoparticles. 
3.5. In vivo MR imaging
As shown in Figure 8, MR signal enhancement was
identified after pMNPs injection to the mice. Initially, T2
time is shortened due to the influx of Manganese ferrite
based contrast agent, resulting in a darker image. And
then enhanced MR imaging signal intensity at the sur-
rounding vessels was simultaneously observed. In T2-
Fig. 5. Cell viabilities of MKN-45 and MKN-28 cells treated
with different concentrations of pMNPs. MKN-45 is CD44
positive cell line and MKN-28 is CD44 negative cell line. This
data showed that pMNPs exhibited no significant proliferation
inhibition (over 80 % cell viability).
Fig. 6. (Color online) Darkfield microscopy images of MKN-
45 cells treated with pMNPs and untreated control cells. (The
scale bar is 10 μm)
Fig. 7. (Color online) Prussian blue staining images of pMNPs-treated MKN-45 cells and MKN-28 cells, respectively (The scale
bar is 10 μm).
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weighted MR images, clear anatomical details were
observed, and there was no artifact due to a difference in
susceptibility. In contrast, in the UTE MR images, an
opposite pattern of obvious enhancement of the MR
imaging signal was observed compared to that of the T2-
weighted MR images after injection of pMNPs. Sequence
details is (a) TR: 4,000 ms, TE: 114 ms, Slice thickness:
1.0 mm, FOV read: 180 mm, coil elements: wrist coil (b)
Fig. 8. (Color online) In vivo MR imaging of MKN-45 xenograft mouse model (a) T2 TSE MR images of xenograft mouse model
after intravenous injection of pMNPs. (b) UTE MR images of tumor-bearing mice after intravenous injection of pMNPs. The scale
bar is 80 mm. 
Fig. 9. Ex vivo MR images (T2 TSE and UTE MR sequence) of mouse organ after injecting pMNPs. The scale bar is 50 mm.
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TR: 6.72 ms, TE:0.07 ms, Slice thickness: 0.6 mm, FOV
read: 110 mm, Coil elements: wrist coil. The same tendency
was observed in vitro as in vivo imaging. After sacrificing
in vivo mice, each representative organ (tumor, liver,
spleen, muscle) was placed in a dish with pbs and
scanned by magnetic resonance imaging. Sequence details
is (a) TR: 4,000 ms, TE: 114 ms, Slice thickness: 1.0 mm,
FOV read: 180 mm, coil elements: wrist coil (b) TR: 6.72
ms, TE: 0.07 ms, Slice thickness: 0.6 mm, FOV read: 110
mm, Coil elements: wrist coil.
3.6. Histological analysis
In Fig. 10, the histological morphology of tumor was
confirmed using H&E staining. We noticed that each of
the cancer cells could be observed through hematoxylin
(nucleus: blue) and eosin Y (cytoplasm: pink) staining. 
4. Discussion
Molecular imaging have been applied to magnetic re-
sonance (MR) imaging for cancer diagnosis. In particular,
various MR sequences with biocompatible polymer-based
magnetic nanoparticles (pMNPs) have been applied for
the MR imaging of cancer. In this study, we confirmed
the T1 and T2 magnetic resonance imaging using polymer
based magnetic nanoparticles in various ways. Owing to
the predominant T2 or T2* effects over the usual dipole-
dipole relaxation mechanism that affects both T1 and T2,
Manganese ferrite nanoparticles are usually treated as T2
or T2* contrast agents. On the other hand, Manganese
ferrite nanoparticles also exhibit a high longitudinal R1
relaxivity providing intrinsic signal enhancement on T1
weighted images. However, conventional imaging sequences
cannot fully take advantage of such strong T1 weighted
contrast effect because of the predominant T2 and spin
dephase effects of Manganese ferrite nanoparticles. Ultra-
short echo time (UTE) imaging is capable of imaging
materials with extremely short T2 and very fast signal
decay. With very short echo time, typically below 0.1 ms,
UTE imaging allows for signal acquisition with little T2
influence. Therefore, we confirmed this using pMNPs.
And also, pMNPs have polymer based targeting modality
that can selectively increase contrast. This makes it possible
to more clearly confirm the contrast enhancement of T1,
T2.17,18,19 To make sure that the pMNP is well synthe-
sized, after amination with polysorbate 80, the peak at the
1650 cm1 region indicated the amide bond of the pMNPs
(Fig. 1, blue arrow). These results clearly demonstrated
that the desired pMNPs were successfully synthesized.
The size of the water-soluble MNPs and pMNPs was
determined to be 77.4 ± 32.4 nm and 137 ± 53.2 nm,
respectively. Thus, the size slightly increased after conju-
gation of pMNPs due to the large molecular weight of the
polymer (HA) of 1000 kDa. In addition, the surface
charge of aminated MNPs also changed from 20.62 ±
1.96 Mv (aminated water-soluble MNPs) to -17.76 ± 1.64
mV (pMNPs) due to the presence of HA (Fig. 3). The
reason why the surface charge changed from positive to
negative is evidence that H.A coated the surface of the
magnetic nanoparticles well. To assess the clinical feasi-
bility of using the prepared pMNPs as MR imaging agents,
we performed MR imaging experiments on solution samples
using the pMNPs exhibiting the strongest magnetic pro-
perties with appropriate size to prolong their retention in
the circulation. As shown in Fig. 4(a), the T2-weighted
MR image exhibited a negative strong intensity (black),
Fig. 10. (Color online) (a) Prussian blue-stained image of the tumor in mouse xenograft model. and (b) image of the boxed section
are magnified of 10 times from (a). Black arrows indicate iron.
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which indicated a decrease in signal intensity owing to
the thicker pMNP solution. In contrast, the UTE MR
solution image demonstrated the opposite deposition
(positive strong intensity: white) due to the very short TE.
This means that the UTE sequence can enable positive
contrast imaging (T1 MRI) without requiring a positive
contrast agent. Comparison of the T2 and UTE intensities
revealed an opposite deposition, which was confirmed by
comparing the T2 intensity with UTE intensity. This
demonstrated that the two types of image contrasts or
weighting (T1/T2) were obtained with a single MR con-
trast agent (T2) (Fig. 4b). Before processing nanoparticles,
cytotoxicity tests were performed to determine the appro-
priate concentration of treatment. MTT Assay is a sensi-
tive, quantitative and reliable colorimetric assay that mea-
sures viability, proliferation and activation of cells. The
assay is based on the capacity of mitochondrial dehydro-
genase enzymes in living cells to convert the yellow
water-soluble substrate 3-(4,5-dimethylthiazol-2-y1)-2,5-
diphenyl tetrazolium bromide (MTT) into a dark blue
formazan product that is insoluble in water. Since this
magnetic nanoparticle has a targeting ability, targeting
ability was confirmed by darkfield microscopy. Darkfield
microscopy images demonstrated that the pMNPs dis-
played excellent binding ability to MKN-45 cells (Fig. 6).
MKN-45 cells treated with pMNPs exhibited a bright
spot, and the membranes of pMNP-treated MKN-45 cells
shone more brightly compared to those of the non-treated
MKN-45 cells. This confirmed that the HA-conjugated
MNPs bound to the CD44 receptors of MKN-45 cells
through receptor-mediated endocytosis. As shown in Fig.
7, Prussian blue staining confirmed the extent of intra-
cellular uptake with pMNPs for both MKN-45 and MKN-
28 cells. Thus, the transport of pMNPs into MKN-45
cells took place efficiency. In contrast, untreated MKN-45
cells and MKN-28 cells exhibited no significant cellular
uptake. The small fractions of iron observed represented
non-specific cellular binding of the MNPs. The UTE MR
images showed a more meaningful result regarding clinical
diagnosis, and could also provide more information than
possible with T2-weighted MR images from a diagnostic
point of view. In area of Nanoscience for MR contrast
agents, T1 and T2 images using contrast agents were only
obtained by injecting the respective contrast agents, or T1,
T2 contrast agents were obtained by making integrated T1/
T2 nanoparticle. Images obtained by injecting each con-
trast agent (T1 and T2) cannot simultaneously obtain
phenomena occurring in viewpoint of nano contrast agents,
and also have a disadvantage in that a synthesis method is
difficult in the case of a contrast agent carrying integrated
T1/T2 nanoparticle. The key of this study is that T2 con-
trast agent (Manganese ferrite based nanoparticles) was
used to confirm the effect of T1 through the UTE sequence
without integrated T1 (Iron oxide)/T2 (Manganese ferrite)
nanoparticle. Previously, a single contrast MR agent (T2)
for a single MR image (T2) was used in contrasting
viewpoints. However, there were limitations in obtaining
two types of image contrasts using the same single con-
trast agent. This study demonstrated that the two types of
images (T1/T2) were obtained with a single MR contrast
agent (T2), and showed the possibility to overcome that
limitation. This enhancement was confirmed by ex vivo
images, it was confirmed in which organs pMNPs
accumulate more in vivo using T2 and UTE sequence
(Fig. 9). Figure 10(b) shows that the iron content (black
arrows) of accumulated pMNPs in the tumors was also
observed by Prussian blue staining. We thus confirmed
that our developed pMNPs had an adequate capability for
targeting CD44-overexpressing gastric cancer. Our study
has some limitations, Firstly, absence of DICOM files and
use of clinical MRI modality rather than animal MRI
modality. As a result, various parameters could not be
adjusted. We are currently planning an experiment using
MRI equipment for only animals, and in the future study,
we will try to improve the research by solving these
problems. Secondly, we has been used as the imaging tool
for identifying magnetic resonance images with a focus
on nanoparticle’s application. In further study, we will
make up in-depth and specific data about magnetic
resonance imaging. 
5. Conclusion
In summary, we synthesized pMNPs as MR imaging
agents for effective diagnosis of CD44-overexpressing
gastric cancer, which was verified in a mouse model.
Development of this contrast agent using pMNPs and
variable MR sequences can help to overcome the diffi-
culty of gastric cancer diagnosis with MR imaging,
especially at an early stage. From a diagnostic point of
view, the ability to simultaneously observe the T1-T2
effect using conventional T2 and UTE is of great signi-
ficance. Consequentially, this work shows potential to
expand the applications of molecular MR imaging to
guide cancer imaging.
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